Navigation Links
Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference

SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference at the Intercontinental Hotel in Boston on August 13, 2009, 2:00 p.m. Eastern Time.


Live audio webcasts of these presentations will be accessible on the Company's website at, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at


    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance

    Porter Novelli Life Sciences
    Jason I. Spark, Vice President

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
3. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
4. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
5. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
6. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
7. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
8. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
11. Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results
Post Your Comments:
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
(Date:10/9/2015)... and ROCKVILLE, Md. , Oct. ... privately-held biotechnology company developing next generation vaccines based ... has entered into an exclusive worldwide licensing agreement ... the treatment or prevention of any and all ... agreement, Immunomic Therapeutics will receive an upfront payment ...
(Date:10/9/2015)... Inc., (NASDAQ: PULM ) will be webcasting the Company,s ... th Annual BIO Investor Forum on Tuesday, October 20, ... --> th Annual BIO Investor Forum on Tuesday, ... --> Pulmatrix will be presenting at the ... October 15, 2015 at 8:30 am EDT. Additionally, the Company ...
(Date:10/9/2015)... ... 09, 2015 , ... Leading microbial genomics startup uBiome today launched the first-ever ... between weight management and the microbiome. The study uses the ResearchKit framework, designed by ... app. , The uBiome app is available as a free download from the App ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to be ... its product to market. The official announcement was recently made ... event in San Francisco , where ... powered by IBM Watson. "It is both an ... 100 companies to bring to market the cognitive power of ...
(Date:9/28/2015)... The global image sensors ... billion by 2020, growing at a CAGR of 4.6% ... Illumination (BSI) technique to improve picture quality are expected ...      (Logo: , The light ... loss and, thus, reduce the noise interference and increase ...
Breaking Biology News(10 mins):